Neuroendocrine tumour
Process to understand the toxic effects of Irinotecan drug on Neuroendocrine cancer patients with UGT1A1 gene modifications: A single center study
Who can joinAsk the trial team
AgeAsk the trial team
Kind of studyObservational: no new treatment
What it testsWatches and records only
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Homi Bhabha Cancer Hospital , VaranasiVaranasi, Uttar PradeshDirections ↗
Registry summary (technical)
Evaluation of UGT1A1 gene polymorphism and Irinotecan toxicity in patients of neuroendocrine carcinoma: A single center comparative observational study - NIL
Sponsor: Mahamana Pandit Madan Mohan Malviya Cancer Centre
CTRI/2025/06/088969 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 12 Jan 2026 · read by us 5 Nov 2026